Janssen promises full focus on Darzalex after defeating Genmab in court

Although a ruling in Janssens favor comes as a slap in the face to its partner Genmab, the former has promised to continue to support bestseller drug Darzalex.

Photo: Piroschka Van De Wouw/Reuters/Ritzau Scanpix

While Genmab remains tight-lipped about its defeat in court over a royalties dispute with partner Janssen, the latter has been a little more outspoken about the expected consequences of the ruling.

”We are proud of our strong partnership and collaboration with Genmab to make a meaningful difference for patients living with multiple myeloma,” Janssen writes in a press release, adding:

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs